ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 341.8% | 5.9% | 651.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 97% | 86.2% | 89.5% | 88.1% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -37.7% | -393.1% | -405.2% | -3,116.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -41.3% | -417% | -421% | -2,803.4% |
| EPS | -1.34 | -13.12 | -13.4 | -12.28 |
| % Growth | 89.8% | 2.1% | -9.1% | – |
| EPS Diluted | -1.34 | -13.12 | -13.4 | -12.28 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | -24.2% | -335% | -375.3% | -2,860.4% |